RaySearch Laboratories AB (publ) (RAY-B)
Stockholm Exchange · Sweden · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 194.90 |
|---|---|
| 52-week range | 153.10 – 259.02 |
| Return, 1 month / 3 months | +10.0% / +13.4% |
| Return, 1 year / 3 years | −15.3% / +128.5% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 49.0% |
| Worst drawdown (1 year) | -34.6% |
| Average daily value traded | 31.38M SEK |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
RaySearch Laboratories develops software for radiation therapy, helping cancer clinics plan and deliver treatment. Its main product, RayStation, lets clinicians model radiation doses, optimise treatment plans and manage patient images, while the company also offers tools for oncology information management and dose calculation. Customers are hospitals and radiotherapy departments that treat cancer patients. The company is based in Stockholm, Sweden, and works with medical device and clinical partners around the world.
On this site RaySearch Laboratories AB (publ) appears as a stock on the Stockholm Exchange (Sweden), code RAY-B, with prices in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
RaySearch Laboratories AB (publ) (RAY-B) trades on the Stockholm Exchange in Sweden. It last closed at SEK 194.90 on 19 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 378 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 15.3% and over the last three months it rose 13.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 54 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.8% | ||
| From 52-week high | -22.4% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 13.4% | ||
| 6-month return | -11.6% | ||
| 12-month return, skipping the last month | -23.0% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 49.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.6% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 31.38M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 27 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 3 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.4% |
|---|---|
| 1 month | +10.0% |
| 3 months | +13.4% |
| 6 months | −11.6% |
| 1 year | −15.3% |
| 3 years | +128.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 182.26 / 193.43 |
|---|---|
| Golden / death cross (60 days) | Death, 47 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.17 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 May 2026 | SEK 4.0000 |
| 23 May 2025 | SEK 3.0000 |
| 23 May 2024 | SEK 2.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.